Anand Anandkumar


Anand is a co-founder and CEO of Bugworks, an Indo-USA-Australia biotech startup, supported by CARB-X, working on tackling the massive problem posed by untreatable bacterial Superbugs which are implicated in hospital/community infections and bio-terrorism situations. More recently the company has also forayed into the design of differentiated Immuno-Oncology assets. Bugworks hopes to make a massive impact on humanity by addressing large unmet medical needs while making its products affordable and accessible to all. The company is supported by bluechip investors from across the globe and has pandemic-preparedness as one of its over-arching goals.

Anand was previously co-founder and Managing Director at Cellworks a Bayarea and Bangalore based company which is a pioneer in using modeling and simulation to support personalized cancer therapy area. Prior to the biotechnology experience, Anand was a professional in the semiconductor industry with about 15 years of global experience in designing high end Integrated Circuits. Chip Design and operations management experience in US/China/Japan/UK and India.

Anand received his bachelor's degree in Electronics and Communication from College of Engineering Guindy, Anna University, India (1986) and a MS & PhD in Electrical and Biomedical engineering from George Washington University in Washington D.C (1992). He won the distinguished alumnus award from Anna University in 2016. He is a member of Eta Kappa Nu and Tau Beta Pi, global engineering honors' committees.

Anand is a globally recognized key opinion leader in the Antimicrobial resistance (AMR)Industry and affiliations include, Member of Executive committee of India biotech association, Member of India advisory board of GARDp, Board member of AMR Industry Alliance, Member of AMR Working Group Bio USA, Co-founder of Indian Electronics and Semiconductor association (IESA), AMR member of G20 health development partnership and speaker in global platforms including the G20, WHO, UN, APIF-Japan etc.